Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
The Translational Medicine Team at BI
Bastani: It takes truly a village to get a drug to launch and I think it was even more than a village at the time. So, we had the entire immunology team actually involved in this. We had the biotherapeutics team, so the molecule makers, without them, we would not have a sizolamat today. And of course, our nonclinical development colleagues, that assessed the safety of the molecules.
Transcript
Play full episode
